<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886571</url>
  </required_header>
  <id_info>
    <org_study_id>119-17-CA</org_study_id>
    <nct_id>NCT03886571</nct_id>
  </id_info>
  <brief_title>U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer</brief_title>
  <official_title>U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoag Memorial Hospital Presbyterian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, biospecimen collection protocol to develop a bank of pancreatic&#xD;
      cancer tissue and normal tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, biospecimen collection protocol to develop a bank of pancreatic&#xD;
      cancer tissue, normal tissue. Biospecimens collected through this protocol will be shared&#xD;
      with collaborators in the Pancreatic Cancer Detection Consortium to support projects funded&#xD;
      through an NIH U01 grant. Participants will be enrolled when they present for clinically&#xD;
      indicated surgical procedures for their possible tumor or pancreas resection or cyst&#xD;
      resection, or at a clinically indicated follow-up appointment after their procedure.&#xD;
&#xD;
      This protocol supports this effort by providing investigators with access to a wide variety&#xD;
      of pancreatic tissues and biospecimens for translational studies in pancreatic cancer. This&#xD;
      protocol covers the collection of clinical data and biospecimens (blood; malignant, benign,&#xD;
      or precancerous pancreatic tumor; and adjacent normal tissues) from patients with, or&#xD;
      suspected to have, pancreatic cancer. Additionally, saliva and cyst fluid, may be collected&#xD;
      in the future from patients with pancreatic cysts. These will be shared with the Pancreatic&#xD;
      Cancer Detection Consortium for further analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2018</start_date>
  <completion_date type="Anticipated">September 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Measuring cell-free and exosomal-miRNA biomarkers using small RNA-Seq in matched tissue and plasma from patients with PDAC, PNs, pancreatitis and normal pancreas for early detection.</measure>
    <time_frame>5 years</time_frame>
    <description>We will perform whole genome small RNA sequencing (small RNA-Seq) analysis on tissue specimens from 60 primary PDACs (30 stage I/II and 30 Stage III/IV), 60 PNs (20 each PanINs, IPMNs and MCNs), and 60 non-neoplastic normal pancreatic tissues (NN) and pancreatitis.&#xD;
We will perform small RNA-Seq analysis to identify differentially expressed cell-free and exosomal miRNAs (cf-miRNAs and exo-miRNAs) from the same matched plasma specimens.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatic Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Up to 60 mL of blood will be obtained at study entry. Archived paraffin embedded blocks of&#xD;
      both normal and tumor tissue and Up to 0.5 mL Pancreatic cyst fluid may be collected if the&#xD;
      participant is undergoing an endoscopic or surgical procedure for a pancreatic cyst.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an upcoming standard of care clinical and/or surgical event who meet criteria&#xD;
        for study participation are identified by the treating physician and will be asked to&#xD;
        participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or Females â‰¥ 18 years of age who have been diagnosed with Pancreatic Cancer&#xD;
             (PDAC), Pancreatic Neoplasms (PNs - IPMMs, PanINs and MCNs), pancreatitis and diabetes&#xD;
             or no disease/healthy.&#xD;
&#xD;
          -  Individuals undergoing or have previously undergone a diagnostic procedure (i.e. EUS&#xD;
             or ERCP) evaluation or surgery.&#xD;
&#xD;
          -  Willingness and ability to donate biospecimens for the purpose of research.&#xD;
&#xD;
          -  Subjects must have had diagnostic procedure or surgery after September 1, 2017.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals under 18 years of age.&#xD;
&#xD;
          -  Inability to donate biospecimens.&#xD;
&#xD;
          -  Females pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Deborah Fridman, PsyD, RN</last_name>
    <phone>949-764-5543</phone>
    <email>Clinicalresearch@hoag.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Andres, MS</last_name>
    <phone>949-764-5543</phone>
    <email>Clinicalresearch@hoag.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Fridman, PsyD, RN</last_name>
      <phone>949-764-5543</phone>
      <email>Clinicalresearch@hoag.org</email>
    </contact>
    <contact_backup>
      <last_name>Leila Andres, MS</last_name>
      <phone>949-764-5543</phone>
      <email>Clinicalresearch@hoag.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Demeure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hoag Memorial Hospital Presbyterian</investigator_affiliation>
    <investigator_full_name>Michael Demeure, MD</investigator_full_name>
    <investigator_title>Program Director for Precision Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

